title: Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review.
abstract: Allogeneic hematopoietic cell transplantation (allo-HCT) is the only known treatment that can offer a cure in mantle cell lymphoma, but it is unclear if regimen dose-intensity offers any advantage. We performed a systematic review/meta-analysis to assess efficacy of allo-HCT using myeloablative or reduced-intensity conditioning. We report results according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. On the basis of a relatively lower nonrelapse mortality and a slightly better progression-free survival/event-free survival and overall survival rates, reduced-intensity allo-HCT regimens appear to be the preferred choice when an allo-HCT is being considered for mantle cell lymphoma. The higher rate of relapse when offering reduced-intensity regimens cannot be ignored but certainly highlights opportunities to incorporate post-transplant strategies to mitigate this risk. A prospective comparative study is ultimately needed to generate more conclusive evidence.
authors.affiliation: Department of Blood & Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL, USA.|Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Kharfan-Dabaja
authors.affiliation: Center for Evidence-Based Medicine, University of South Florida, Tampa, FL, USA.
authors.forename: Tea
authors.initials: T
authors.lastname: Reljic
authors.affiliation: Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
authors.forename: Jessica
authors.initials: J
authors.lastname: El-Asmar
authors.affiliation: Department of Blood & Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL, USA.|Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
authors.forename: Taiga
authors.initials: T
authors.lastname: Nishihori
authors.affiliation: Department of Blood & Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, FL, USA.|Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
authors.forename: Ernesto
authors.initials: E
authors.lastname: Ayala
authors.affiliation: Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
authors.forename: Mehdi
authors.initials: M
authors.lastname: Hamadani
authors.affiliation: Center for Evidence-Based Medicine, University of South Florida, Tampa, FL, USA.
authors.forename: Ambuj
authors.initials: A
authors.lastname: Kumar
mesh_terms: D018572:Disease-Free Survival; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000473:pathology / Q000628:therapy*; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods*; D014184:Transplantation, Homologous
keywords: allogeneic hematopoietic cell transplantation; mantle cell lymphoma; survival